Search Results
Your search for all items matches 36637 pages
Showing 1 - 50Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer
Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer derived from screening mammograms evolve over time and differ between women who develop cancer and those who do not, opening the door to a new era of dynamic breast cancer risk assessment. The new...
FDA Approves Capivasertib Plus Abiraterone With ADT/Prednisone in Patients With mHSPC
The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of PTEN-deficient metastatic androgen pathway modulation-naive or sensitive (mAPMN/S) prostate cancer (also referred to as metastatic hormone-sensitive...
ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial
ASCO has announced a collaboration with Ryght AI aimed at accelerating the identification and activation of research sites for the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study, a clinical trial evaluating different starting doses of CDK4/6 inhibitors in patients with metastatic breast cancer. The...
Update to ASCO Guideline on Advanced NSCLC Without Driver Alterations Adds Retifanlimab to Treatment Options
ASCO has issued an update to its living guideline on systemic therapies for patients with stage IV NSCLC without driver alterations.1 The update, which includes a new recommendation regarding the PD-1 inhibitor retifanlimab-dlwr and chemotherapy, follows a recent full update to the guideline...
Next-Generation KRAS Inhibitors Show Promising Activity in Advanced Non–Small Cell Lung Cancer
Two investigational KRAS inhibitors showed activity in previously treated KRAS-mutant non–small cell lung cancer (NSCLC), according to findings presented during the Clinical Trials Plenary Session at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego. Elisrasib was ...
FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC
On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved the antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) for two indications in adults with triple-negative breast cancer (TNBC). The first indication, supported by data from ASCENT-03, is for sacituzumab govitecan as a ...
SENOMAC Trial: Omission of Completion Axillary Dissection Is Oncologically Safe in Expanded Breast Cancer Population
The international non-inferiority SENOMAC trial has confirmed that omitting completion axillary lymph node dissection (ALND) is oncologically safe (ie, a less intensive approach does not compromise outcomes) and substantially reduces patient-reported arm morbidity in patients with one or two...
Breast Cancer: Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease
On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved palbociclib (Ibrance) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor (HR)-positive, HER2-positive locally advanced or...
Educational Gaps Found in Cardio-Oncology Training
Educational gaps in cardio-oncology training have been identified in the results of an international survey presented at the European Society of Cardiology (ESC) Congress 2026. “The survey identified profound gaps in cardio-oncology education during medical school and residency and in structured...
TAPUR Marks a Decade of Innovation
In 2013, during the ASCO Annual Meeting, Richard L. Schilsky, MD, FACP, FSCT, FASCO, then ASCO’s Chief Medical Officer, presented a bold clinical trial concept during an educational session on the challenges of delivering precision medicine services in an oncology community care setting. The idea...
Abemaciclib Reduces Disease Progression, Death in Rare, Aggressive Soft-Tissue Sarcoma
In the treatment of advanced dedifferentiated liposarcoma, a rare and aggressive soft-tissue sarcoma, the CDK4/6 inhibitor abemaciclib significantly reduced the risk of disease progression or death by 62% as compared with placebo in the randomized phase III SARC041 study.1 Mark Dickson, MD, of...
Talquetamab Combinations in Relapsed or Refractory Myeloma
In an interim analysis of a phase III trial (MonumenTAL-3) reported in The New England Journal of Medicine, Mina et al found that the combinations of talquetamab with daratumumab/pomalidomide (Tal-DP) and talquetamab plus daratumumab (Tal-D) improved progression-free survival vs...
Advanced Breast Cancer: Novel CDK4/6 Inhibitor Plus an Aromatase Inhibitor
In an interim analysis of a Chinese phase III trial (FCN-437c-III201) reported in JAMA Oncology, Yuan et al found that the addition of the novel CDK4/6 inhibitor fovinaciclib to aromatase inhibitor therapy was associated with significant improvement in progression-free survival in the first-line...
Wearable Devices May Help Detect CRS Earlier in Patients With Myeloma Receiving CAR T-Cell Therapy
Researchers have found that wearable devices may help clinicians detect cytokine-release syndrome—a common and potentially serious side effect of chimeric antigen receptor (CAR) T-cell therapy—hours earlier than standard hospital monitoring in patients with multiple myeloma. The findings,...
New Section Chief of Medical Oncology and Hematology and Deputy Director for Clinical Affairs for Yale Cancer Center and Smilow Cancer Hospital Named
Ian E. Krop, MD, PhD, has been named as Section Chief of Medical Oncology and Hematology and Deputy Director for Clinical Affairs for Yale Cancer Center and Smilow Cancer Hospital. Dr. Krop is an international leader in breast cancer care and clinical investigation. He joined Yale in 2022 and is a...
Case 3: Patient With Richter Transformation Refractory to Pola-R-CHP
This is Part 3 of CLL Treatment Sequencing: Where Do Next-Generation BTK Inhibitors Fit?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Mazyar Shadman, MD, MPH, Inhye Ahn, MD, and Deborah M. Stephens, DO, discuss the management...
Case 2: Patient With Double-Refractory High-Risk CLL
This is Part 2 of CLL Treatment Sequencing: Where Do Next-Generation BTK Inhibitors Fit?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Mazyar Shadman, MD, MPH, Inhye Ahn, MD, and Deborah M. Stephens, DO, discuss treatment...
Case 1: Patient With BTK C481S Resistance Mutation Following Acalabrutinib/Obinutuzumab
This is Part 1 of CLL Treatment Sequencing: Where Do Next-Generation BTK Inhibitors Fit?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Mazyar Shadman, MD, MPH, Inhye Ahn, MD, and Deborah M. Stephens, DO, discuss treatment...
Impact of Early Palliative Care on Quality of Life in Patients With Breast Cancer in India
Early integration of palliative, or supportive, care at the time of breast cancer diagnosis improved quality of life more than on-demand palliative care in a randomized trial of patients in India. The research was highlighted in a media briefing ahead of the 2026 ASCO Breakthrough Meeting, taking...
Chinese Study of HER2-Targeted Combination in Neoadjuvant Therapy for Locally Advanced Breast Cancer
A HER2-targeted regimen produced high pathologic complete response rates before surgery in patients with locally advanced HER2-positive breast cancer, according to results from a single-arm phase II neoadjuvant trial conducted in China. The research was highlighted in a media briefing ahead of the...
GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD
A large retrospective cohort study found that GLP-1 receptor agonist use was associated with significantly lower 5-year rates of colorectal cancer among patients with inflammatory bowel disease (IBD). The research was highlighted in a media briefing ahead of the 2026 ASCO Breakthrough Meeting,...
Subgroup Analysis of Inavolisib Regimen in Asian Patients With Advanced Breast Cancer
Treatment with the PI3K inhibitor inavolisib in combination with palbociclib and fulvestrant produced substantial clinical benefits in Asian patients with PIK3CA-mutated, hormone receptor–positive (HR-positive), HER2-negative, endocrine-resistant advanced breast cancer, according to a subgroup...
Multi-Cancer Early Detection Test Evaluated in Real-World Asian Cohort
A large real-world study conducted across six Asian countries suggests that a blood-based multi-cancer early detection (MCED) test may accurately identify multiple cancer types in routine clinical practice, including cancers for which no standard screening programs currently exist. The research was ...
Addition of Mezigdomide to Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma
In an interim analysis of a phase III trial (SUCCESOR-2) reported in The Lancet, Dimopoulos et al found that the addition of the cereblon E3 ligase modulator mezigdomide to carfilzomib/dexamethasone significantly improved progression-free survival in previously treated patients with relapsed or...
Ga-68–PSMA-11 PET/CT in Diagnosis of Prostate Cancer
In an Australian phase III noninferiority trial reported in The Lancet Oncology, Buteau et al found that use of gallium-68–labeled PSMA-11 (Ga-68–PSMA-11) positron-emission tomography/computed tomography (PET/CT) could improve the pathway of diagnosis of prostate cancer in men with clinical...
Aumolertinib Plus Chemotherapy in EGFR-Mutated Advanced NSCLC
In a Chinese phase III trial (AENEAS2) reported in The Lancet Oncology, Li et al found that the combination of aumolertinib with chemotherapy significantly improved progression-free survival vs aumolertinib alone in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC). Study...
AI-Assisted Tumor Volume Response Criteria Outperform Physician Assessments and RECIST Criteria in Pleural Mesothelioma
Researchers have developed and validated an artificial intelligence (AI)‒assisted volumetric response criteria for assessing response in pleural mesothelioma. The AI-backed criteria outperformed both humans and standard international Response Evaluation Criteria in Solid Tumors (RECIST) criteria,...
AGA Recommends Colonoscopy Over Alternative Colorectal Cancer Screening Methods
The American Gastroenterological Association (AGA) recently reported that among expanding options for colorectal cancer screening, colonoscopy remains the AGA's top recommendation. In a business announcement, the organization noted that new screening guidance has alerted patients and primary care...
FDA Warns of Ongoing Breast Biopsy Needle Shortage
The U.S. Food and Drug Administration (FDA) issued notice of supply chain interruptions for stereotactic breast biopsy needles due to recent supplier issues. Disruption in biopsy needle manufacturing is expected to impact patient care and could require adjustments for the management of patients...
St. Jude Redesignation Marks Collaboration With WHO Toward Improved Pediatric Cancer Outcomes Globally
St. Jude Children's Research Hospital has announced that they have been redesignated as a World Health Organization (WHO) Collaborating Centre for Childhood Cancer. The new designation recognizes the work of St. Jude to support WHO in integrating childhood cancer into national cancer control plans; ...
Preclinical Research Shows IFN-γ May Attenuate Neutrophil Response to Cancer Immunotherapy
Researchers have discovered that the type II interferon, interferon-γ, may impact how neutrophils react to immunotherapy, either supporting or blocking the treatment for patients with cancer, according to study findings published in Immunity. Study Methods and Key Findings Researchers analyzed two...
Jennifer A. Woyach, MD, on Pretreated Relapsed or Refractory CLL/SLL: Ongoing ROCKET-CLL Trial
Jennifer A. Woyach, MD, of The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, discusses the ongoing, actively recruiting ROCKET-CLL trial, which is a phase III study aiming to compare the efficacy of rocbrutinib vs pirtobrutinib in patients...
Low-Dose Tamoxifen in Noninvasive Breast Neoplasia
In a long-term individual patient-level pooled analysis reported in the Journal of Clinical Oncology, Gandini et al found that low-dose tamoxifen was associated with good outcomes in patients with noninvasive breast neoplasia. Study Details The study used individual patient data from three clinical ...
Relapsed or Refractory Multiple Myeloma: Talquetamab/Daratumumab
Patients with multiple myeloma who received a new immunotherapy combination had significantly longer progression-free survival and showed early signs of improved overall survival, according to findings from the phase III MonumenTAL-3 trial. Peter M. Voorhees, MD, Professor of Medicine at Wake...
New ACSM Expert Consensus Statement: Exercise in Children and Adolescents With Cancer
In children and adolescents undergoing cancer treatment, exercise can be performed safely during and after therapy when appropriately supervised and individualized; further, appropriately prescribed exercise should be included as part of supportive cancer care, according to a new American College...
Thyroid Cancer: Reproductive Lifespan, Hormone Therapy Potentially Linked to Incidence
Longer exposure to hormone replacement therapy and longer reproductive lifespan showed potential associations with increased thyroid cancer risk in women, according to findings presented at ENDO 2026 (Abstract ORF12-08). “These results show how common life events in women, such as the timing of...
Two-Pronged Nudges Result in Timely Conversations Around Priorities of Cancer Care
Small, targeted reminders for both clinicians and patients to have serious illness conversations led to a significant increase in the number of conversations recorded, allowing for oncologists to better honor patients' goals and wishes for their cancer care, according to findings of a randomized...
MIBC: Intravesical Recombinant BCG and Chemoimmunotherapy
In a Swiss phase II trial (SAKK 06/19) reported at the 2026 ASCO Annual Meeting (Abstract 4503) and published in the Journal of Clinical Oncology, Cathomas et al found that the addition of intravesical recombinant bacillus Calmette-Guérin (rBCG) to perioperative chemoimmunotherapy was associated...
Neoadjuvant Sacituzumab Govitecan in MIBC
In an Italian phase II trial (SURE-01) reported in the Journal of Clinical Oncology, Necchi et al found that neoadjuvant sacituzumab govitecan was active in patients with muscle-invasive bladder cancer (MIBC) who were ineligible for or elected not to receive neoadjuvant chemotherapy. Study Details...
Metastatic Colorectal Cancer: GUCY2C-Targeted CAR T-Cell Therapy
In a Chinese phase I dose-escalation and dose-expansion study reported in the Journal of Clinical Oncology, Qi et al found that guanylyl cyclase 2C (GUCY2C)-targeted chimeric antigen receptor (CAR) T-cell therapy had an “acceptable” safety profile and was active in patients with previously treated...
Lu-177 Dotatate in Metastatic Pancreatic Neuroendocrine Tumors
In a French phase II noncomparative trial (OCLURANDOM) reported in The Lancet Oncology, Baudin et al found that lutetium Lu-177 dotatate (Lu-177 dotatate) produced numerically better progression-free survival results than those achieved with sunitinib when used as an internal control in patients...
Paolo Tarantino, MD, PhD, on HER2-Positive Metastatic Breast Cancer: Overall Survival by Genomic Profile
Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute, reviews the results of a large clinicogenomic database study that looked at overall survival by genomic profile among patients with HER2-positive metastatic breast cancer. Patients with mutations in key DNA repair genes experienced a...
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic...
Adjuvant Belzutifan in Combination With Pembrolizumab Receives FDA Approval in Renal Cell Carcinoma
Earlier this month, the U.S. Food and Drug Administration (FDA) approved the hypoxia-inducible factor-2 alpha inhibitor belzutifan (Welireg) in combination with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of adults with renal...
François-Clément Bidard, MD, PhD, on Advanced Breast Cancer With Emergent ESR1 Mutations: First-Line Option
François-Clément Bidard, MD, PhD, of Institut Curie, presents final progression-free survival 2 findings from the phase III SERENA-6 trial, which investigated the efficacy of camizestrant, a selective estrogen receptor degrader (SERD), vs continued aromatase inhibition in patients with advanced...
Gerneiva Parkinson, MD, on Time on Systemic Therapy for Patients With HR-Positive Breast Cancer and a Pathogenic Variant
Gerneiva Parkinson, MD, of Stanford Cancer Institute, discusses time on treatment for systemic therapies among women with hormone receptor (HR)-positive breast cancer and a pathogenic variant in BRCA1, BRCA2, or PALB2 (Abstract 1096).
Siddhartha Yadav, MBBS, MD, on Germline Pathogenic Variants Among Patients With Breast or Ovarian Cancer
Siddhartha Yadav, MBBS, MD, of Mayo Clinic Rochester, talks about a real-world evaluation of germline pathogenic variants in cancer predisposition genes in unselected South Asian women with breast or ovarian cancer (Abstract 10513).
Martine J. Piccart-Gebhart, MD, PhD, on Personalizing Treatments in HR-Positive/HER2-Negative Breast Cancer
Martine J. Piccart-Gebhart, MD, PhD, of Jules Bordet Institute, Université Libre de Bruxelles, reviews multiple abstracts discussing avenues of personalized treatment for patients with hormone receptor (HR)-positive, HER2-negative breast cancer, including genomic testing and systemic therapy.
TP53 Mutation Acquisition Timing Influences Prognosis in MPNs, Study Finds
The timing of TP53 mutation acquisition carries important prognostic implications for patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes/MPN overlap disorders. Later emergence of the mutation is associated with significantly worse survival outcomes, according to a...
Machine Learning Model May Improve Accuracy of Liquid Biopsy Results
A machine learning model developed by researchers at the Johns Hopkins Kimmel Cancer Center filters out the biological noise in liquid biopsy samples, helping clinicians better match therapies to their patients’ tumors. These findings were published by Canzoniero et al in Clinical Cancer Research....
